Michele Ceribelli

机构：National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences, National Blood Clot Alliance · ORCID：0000-0001-9857-9521

发表论文 351 篇 · 总被引 5816 次 · h-index 33

代表论文

• BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML (2025 · Leukemia · 被引 2)
• Therapeutic NAMPT inhibition reveals a targetable metabolic vulnerability in neuroblastoma (2026 · Journal of Experimental & Clinical Cancer Research)
• Prophylactic inhibition of LATS1/2 before high-dose irradiation promotes the regeneration of the damaged intestinal epithelium (2026 · npj Regenerative Medicine)
• Cysteine-mediated bortezomib resistance is governed by α-ketoacid availability (2026 · bioRxiv (Cold Spring Harbor Laboratory))
• Abstract A027: Combination targeted therapy with ViPOR in relapsed/refractory (R/R) and treatment-naïve (TN) mantle cell lymphoma (MCL): Analysis of safety, efficacy, and minimal residual disease (MRD) (2026 · Blood Cancer Discovery)
• Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate Cancer (2026 · bioRxiv (Cold Spring Harbor Laboratory))